|
|
|
|
|
| | |
|
Year
|
Test Article
|
Phase
|
Protocol
|
Countries/Sites
|
Client
|
Sponsor
|
|
2006
|
Monoclonal antibody
|
II (orphan)
|
Open label, parallel group, 24 patients. Mycosis fungoides (non-Hodgkins lymphoma)
|
Germany, Spain, Italy. 12
|
Global CRO
|
EU biotech
|
|
2006
|
Implantable drug-eluting device
|
II (for CE marking)
|
Single blind, parallel group, 120 patients. Renal dialysis.
|
UK. 11
|
Global CRO
|
US device company
|
|
2005-06
|
Phosphorus binder
|
I
|
Double blind, parallel group, pharmacodynamic equivalence study. 24 healthy volunteers. Drug indication: end stage renal failure
|
UK. 1
|
Mid-sized pharma company
|
Mid-sized UK pharma company
|
|
2004
|
Gene therapy for coronary artery patency, using viral vector
|
II
|
Double blind, parallel group, placebo controlled, 129 patients. Angina pectoris
|
UK.2
|
Small CRO
|
US biotech
|
|
2003
|
M1 receptor agonist
|
I
|
Open label ADME study. 8 healthy volunteers. Drug indication: insomnia
|
UK. 1
|
Japanese pharma
|
Japanese pharma
|
|
2001-02
|
Immunomodulator
|
IIa
|
Double blind, parallel group, placebo controlled, 120 patients. Atopic dermatitis
|
UK, Poland. 6
|
Japanese pharma
|
Japanese pharma
|
|
|
|
|
|
|
|
|
